odevixibat Albireo Announces U.S. FDA Acceptance of New Drug Application for Odevixibat BOSTON, Jan. 25, 2021 (GLOBE NEWSWIRE) — Albireo Pharma, Inc. (Nasdaq: ALBO),

Continue reading »